NCT07070648View on ClinicalTrials.gov

Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET

RecruitingOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

May 9, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions

Diffuse Large B-Cell LymphomaDLBCL

Interventions

DRUG

POLA-R-CHP

Pola-R-CHP treatment for 6 cycles (IPI score 2-5)

Trial Locations (1)

China

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER